Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)

Inclusion Criteria

• •Elderly patients 75 years old or more
• •Life expectancy of greater then or equal to 6 months
• •Histologically proven metastatic breast or colorectal cancer, requiring a chemotherapy by capecitabine according to the habitual schema
• •Metastatic situation whatever treatment line
• •Previous hormonotherapy for breast cancer, prior chemotherapy (without capecitabine) in adjuvant and/or metastatic indication (colorectal or breast cancer), or radiotherapy (colorectal or breast cancer) are allowed
• •One or more measurable target lesion (RECIST criteria)
• •ADL\>4 (geriatric scales)
• •GSD\<12 (geriatric scales)
• •Laboratory values :
• •creatinine clearance (CrCl) \>=30 mL/min according to Cockcroft formula
• •Adequate bone marrow function (neutrophils count \> 1.5 x 10\^9/L, platelets \> 100 x 10\^9/L, hemoglobin \[Hb\] \> 10g/dl)
• •Adequate hepatic function: total bilirubin \< 1,5 x upper normal limit, aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) \< 2,5x upper normal limits (in case of liver metastases \< 5 x upper normal limits)
• •Alcalin phosphatases \<=2,5x ULN (\<=5 x ULN if liver metastases present).
• •Subjects must be willing to be followed during the course of treatment/observation and follow-up.
• •Signed written informed consent before first course of chemotheray